An update on computational oral absorption simulation
暂无分享,去创建一个
[1] M E Andersen,et al. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. , 1995, Toxicology letters.
[2] M. DeVito,et al. Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.
[3] Jan Meulenbelt,et al. A Human Physiologically-Based Model for Glycyrrhzic Acid, A Compound Subject to Presystemic Metabolism and Enterohepatic Cycling , 2000, Pharmaceutical Research.
[4] V. Lukacova,et al. Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects , 2009, The AAPS Journal.
[5] Stefan S De Buck,et al. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation , 2007, Expert opinion on drug metabolism & toxicology.
[6] Jürgen B. Bulitta,et al. Physiologically Based Pharmacokinetics of Zearalenone , 2009, Journal of toxicology and environmental health. Part A.
[7] A. Galetin,et al. Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption. , 2009, Journal of pharmaceutical sciences.
[8] K. Higaki,et al. Prediction of the Plasma Concentration Profiles of Orally Administered Drugs in Rats on the Basis of Gastrointestinal Transit Kinetics and Absorbability , 1997, The Journal of pharmacy and pharmacology.
[9] J. Wagner,et al. KINETIC ANALYSIS OF BLOOD LEVELS AND URINARY EXCRETION IN THE ABSORPTIVE PHASE AFTER SINGLE DOSES OF DRUG. , 1964, Journal of pharmaceutical sciences.
[10] Isadore Kanfer,et al. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[11] Michael B. Bolger,et al. In Silico Modeling of Non-Linear Drug Absorption for the P-gp Substrate Talinolol and of Consequences for the Resulting Pharmacodynamic Effect , 2006, Pharmaceutical Research.
[12] Hiroshi Yamazaki,et al. Human Blood Concentrations of Cotinine, a Biomonitoring Marker for Tobacco Smoke, Extrapolated from Nicotine Metabolism in Rats and Humans and Physiologically Based Pharmacokinetic Modeling , 2010, International journal of environmental research and public health.
[13] M. Jamei,et al. PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. , 2010, Toxicology.
[14] David G Levitt,et al. PKQuest: measurement of intestinal absorption and first pass metabolism – application to human ethanol pharmacokinetics , 2002, BMC clinical pharmacology.
[15] T. Kararli. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals , 1995, Biopharmaceutics & drug disposition.
[16] Raimar Löbenberg,et al. Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[17] Tycho Heimbach,et al. Practical Anticipation of Human Efficacious Doses and Pharmacokinetics Using In Vitro and Preclinical In Vivo Data , 2009, The AAPS Journal.
[18] D T Mauger,et al. In vitro-in vivo relationships for oral extended-release drug products. , 1997, Journal of biopharmaceutical statistics.
[19] Michael B. Bolger,et al. Prediction of Modified Release Pharmacokinetics and Pharmacodynamics from In Vitro, Immediate Release, and Intravenous Data , 2009, The AAPS Journal.
[20] A Rostami-Hodjegan,et al. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. , 2010, Current drug metabolism.
[21] R. J. Lutz,et al. A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[22] J. F. Gross,et al. Physiologically based pharmacokinetic models for anticancer drugs , 2004, Cancer Chemotherapy and Pharmacology.
[23] J. Wagner,et al. Absorption of Flurbiprofen in the Fed and Fasted States , 1992, Pharmaceutical Research.
[24] C. Goodman. United States Pharmacopeial Convention , 1988 .
[25] Stefan Willmann,et al. Development and Validation of a Physiology-based Model for the Prediction of Oral Absorption in Monkeys , 2007, Pharmaceutical Research.
[26] M. Pocard,et al. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass. , 2010, Molecular pharmaceutics.
[27] Guanghua Gao,et al. Physiologically Based Pharmacokinetics of Matrine in the Rat after Oral Administration of Pure Chemical and ACAPHA , 2009, Drug Metabolism and Disposition.
[28] Hiroshi Yamazaki,et al. Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. , 2010, Regulatory toxicology and pharmacology : RTP.
[29] Ivan Nestorov,et al. Whole-body physiologically based pharmacokinetic models , 2007, Expert opinion on drug metabolism & toxicology.
[30] M. Rowland,et al. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.
[31] K. Pang,et al. A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[32] M. Jamei,et al. A Novel Physiologically-Based Mechanistic ModelPredicting Oral Drug Absorption: The Advanced Dissolution, Absorption, and Metabolism (ADAM) Model , 2007 .
[33] J. Parojčić,et al. In Vitro–In Vivo Correlation for Gliclazide Immediate-Release Tablets Based on Mechanistic Absorption Simulation , 2011, AAPS PharmSciTech.
[34] Jennifer B Dressman,et al. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[35] Masoud Jamei,et al. Prediction of intestinal first-pass drug metabolism. , 2007, Current drug metabolism.
[36] Thierry Lavé,et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. , 2005, Journal of pharmaceutical sciences.
[37] Jin Y. Jin,et al. Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism. , 2010, Journal of pharmaceutical sciences.
[38] J. Dressman,et al. Mixing-tank model for predicting dissolution rate control or oral absorption. , 1986, Journal of pharmaceutical sciences.
[39] Chensheng Lu,et al. The Implications of Using a Physiologically Based Pharmacokinetic (PBPK) Model for Pesticide Risk Assessment , 2009, Environmental health perspectives.
[40] H J Clewell,et al. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. , 1997, Journal of the American Academy of Dermatology.
[41] J. Fisher,et al. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models. A two-compartment description. , 1991, Drug metabolism and disposition: the biological fate of chemicals.
[42] H. Lennernäs,et al. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. , 2004, Molecular pharmaceutics.
[43] Filippos Kesisoglou,et al. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[44] L Zhang,et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.
[45] M. Andersen,et al. Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. , 2007, Toxicology.
[46] Wolfgang Weiss,et al. A Computational Systems Biology Software Platform for Multiscale Modeling and Simulation: Integrating Whole-Body Physiology, Disease Biology, and Molecular Reaction Networks , 2011, Front. Physio..
[47] M E Meek,et al. Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. , 2003, Regulatory toxicology and pharmacology : RTP.
[48] Sarah Whalley,et al. Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling , 2010, Clinical pharmacokinetics.
[49] J. Morais,et al. The new European Medicines Agency guideline on the investigation of bioequivalence. , 2010, Basic & clinical pharmacology & toxicology.
[50] Alan Jones,et al. To whom correspondence should be addressed , 2014 .
[51] Jennifer B Dressman,et al. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[52] Filippos Kesisoglou,et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[53] Stefan Willmann,et al. Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption. , 2009, The Journal of pharmacy and pharmacology.
[54] A. McLachlan,et al. Physiologically Based Pharmacokinetic Model for Terbinafine in Rats and Humans , 2002, Antimicrobial Agents and Chemotherapy.
[55] Martin Kuentz,et al. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[56] M. Rowland,et al. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.
[57] Nigel J Walker,et al. Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. , 2002, Regulatory toxicology and pharmacology : RTP.
[58] Michael B. Bolger,et al. Simulations of the Nonlinear Dose Dependence for Substrates of Influx and Efflux Transporters in the Human Intestine , 2009, The AAPS Journal.
[59] Sheila Annie Peters,et al. Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[60] L. A. Fenu,et al. The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools , 2007, Drug Metabolism and Disposition.
[61] Harvey Wong,et al. Interplay of Dissolution, Solubility, and Nonsink Permeation Determines the Oral Absorption of the Hedgehog Pathway Inhibitor GDC-0449 in Dogs: An Investigation Using Preclinical Studies and Physiologically Based Pharmacokinetic Modeling , 2010, Drug Metabolism and Disposition.
[62] Walter Schmitt,et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. , 2008, Expert opinion on drug metabolism & toxicology.
[63] R. Saito,et al. Quantitative analysis of the effect of supersaturation on in vivo drug absorption. , 2010, Molecular pharmaceutics.
[64] Tau Fluvalinate,et al. The European Agency for the Evaluation of Medicinal Products , 1997 .
[65] F Kesisoglou,et al. Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[66] G. Amidon,et al. Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.
[67] J. Dressman,et al. Towards Quantitative Prediction of Oral Drug Absorption , 2008, Clinical pharmacokinetics.
[68] I. Gardner,et al. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man. , 2008, Xenobiotica; the fate of foreign compounds in biological systems.
[69] F. Theil,et al. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. , 2000, Journal of pharmaceutical sciences.
[70] H. Métivier. A new model for the human alimentary tract: the work of a Committee 2 task group. , 2003, Radiation protection dosimetry.
[71] Xh Huang,et al. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications , 2010 .
[72] S. Yamashita,et al. Rate-Limiting Steps of Oral Absorption for Poorly Water-Soluble Drugs in Dogs; Prediction from a Miniscale Dissolution Test and a Physiologically-Based Computer Simulation , 2008, Pharmaceutical Research.
[73] L. A. Fenu,et al. Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs , 2007, Drug Metabolism and Disposition.
[74] Patrick Poulin,et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. , 2003, Toxicology letters.
[75] A. Oomen,et al. Development of an In Vitro Digestion Model for Estimating the Bioaccessibility of Soil Contaminants , 2003, Archives of environmental contamination and toxicology.
[76] K. Bischoff,et al. Models of ARA-C chemotherapy of L1210 leukemia in mice , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[77] Walter Schmitt,et al. A physiological model for the estimation of the fraction dose absorbed in humans. , 2004, Journal of medicinal chemistry.
[78] H. Haggard,et al. THE ABSORPTION, DISTRIBUTION, AND ELIMINATION OF ETHYL ETHER , 1957 .
[79] Walter Schmitt,et al. Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.
[80] H. Haggard. I. THE AMOUNT OF ETHER ABSORBED IN RELATION TO THE CONCENTRATION INHALED AND ITS FATE IN THE BODY , 1924 .
[81] Ryosei Kawai,et al. Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125 , 1994, Journal of Pharmacokinetics and Biopharmaceutics.
[82] John G. Wagner,et al. Fundamentals of Clinical Pharmacokinetics , 1975 .
[83] G L Amidon,et al. A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.
[84] Matthew A. Bazar,et al. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats , 2009, Journal of applied toxicology : JAT.
[85] Sang Wook Hwang,et al. Assessment of Bisphenol a Exposure in Korean Pregnant Women by Physiologically Based Pharmacokinetic Modeling , 2010, Journal of toxicology and environmental health. Part A.
[86] A. Brochot,et al. Physiologically based pharmacokinetic/pharmacodynamic animal-to-man prediction of therapeutic dose in a model of epilepsy. , 2010, Basic & clinical pharmacology & toxicology.
[87] Michael Levin. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .
[88] Patrick Poulin,et al. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.
[89] Yasuhiro Tsume,et al. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. , 2010, Molecular pharmaceutics.
[90] Kazutaka Higaki,et al. Gastrointestinal transit and drug absorption. , 2000, Biological & pharmaceutical bulletin.
[91] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[92] Y. Liu,et al. A physiologically based pharmacokinetic model for valnemulin in rats and extrapolation to pigs. , 2011, Journal of veterinary pharmacology and therapeutics.
[93] J. Dressman,et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. , 2011, Journal of pharmaceutical sciences.
[94] G. Grass,et al. Simulation models to predict oral drug absorption from in vitro data , 1997 .
[95] G L Amidon,et al. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[96] Fan Zhang,et al. Whole-Body Physiologically Based Pharmacokinetic Model for Nutlin-3a in Mice after Intravenous and Oral Administration , 2011, Drug Metabolism and Disposition.
[97] Sebastian Polak,et al. Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.
[98] A. Urtti,et al. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[99] Andrea N. Edginton,et al. Predicting Plasma Concentrations of Bisphenol A in Children Younger Than 2 Years of Age after Typical Feeding Schedules, using a Physiologically Based Toxicokinetic Model , 2008, Environmental health perspectives.
[100] Thierry Lavé,et al. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man. , 2005, Basic & clinical pharmacology & toxicology.
[101] S. Willmann,et al. Risk to the Breast‐Fed Neonate From Codeine Treatment to the Mother: A Quantitative Mechanistic Modeling Study , 2009, Clinical pharmacology and therapeutics.
[102] Jelena Parojcić,et al. Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. , 2009, Molecular pharmaceutics.
[103] M. Andersen,et al. A physiologically based pharmacokinetic description of the oral uptake, tissue dosimetry, and rates of metabolism of bromodichloromethane in the male rat. , 1998, Toxicology and applied pharmacology.
[104] Rogelio Tornero-Velez,et al. Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. , 2010, Toxicology and applied pharmacology.
[105] P J Sinko,et al. Development of predictive pharmacokinetic simulation models for drug discovery. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[106] Kenneth B. Bischoff,et al. Mathematical representations of cancer chemotherapy effects , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[107] Thierry Lavé,et al. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[108] Malcolm Rowland,et al. Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.
[109] T. Lavé,et al. A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics , 2006, Clinical pharmacokinetics.
[110] Michael B. Bolger,et al. Application of Gastrointestinal Simulation for Extensions for Biowaivers of Highly Permeable Compounds , 2008, The AAPS Journal.
[111] Thierry Lavé,et al. Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling , 2006, Clinical pharmacokinetics.
[112] Robert Tardif,et al. Development of Physiologically Based Toxicokinetic Models for Improving the Human Indoor Exposure Assessment to Water Contaminants: Trichloroethylene and Trihalomethanes , 2006, Journal of toxicology and environmental health. Part A.
[113] Raimar Löbenberg,et al. Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug , 2008, Pharmaceutical Research.
[114] Simon Thomas,et al. Simulation modelling of human intestinal absorption using Caco-2 permeability and kinetic solubility data for early drug discovery. , 2008, Journal of pharmaceutical sciences.
[115] G. Levy. EFFECT OF DOSAGE FORM ON DRUG ABSORPTION A FREQUENT VARIABLE IN CLINICAL PHARMACOLOGY. , 1964, Archives internationales de pharmacodynamie et de therapie.
[116] J. Dressman,et al. Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. , 2010, Journal of pharmaceutical sciences.
[117] Chad Stoner,et al. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability. , 2006, International journal of pharmaceutics.
[118] Stefan Willmann,et al. Physiology-Based Simulations of a Pathological Condition , 2008, Clinical pharmacokinetics.
[119] Torsten Teorell,et al. Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .
[120] Edda Klipp,et al. Systems Biology , 1994 .
[121] J. Dressman,et al. Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.
[122] Hugh A. Barton,et al. Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.
[123] Donald E Mager,et al. Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice. , 2004, Drug metabolism and disposition: the biological fate of chemicals.
[124] Sheila Annie Peters,et al. Identification of Intestinal Loss of a Drug through Physiologically Based Pharmacokinetic Simulation of Plasma Concentration-Time Profiles , 2008, Clinical pharmacokinetics.
[125] Umesh V. Banakar,et al. Pharmaceutical Dissolution Testing , 1991 .
[126] K. Pang,et al. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[127] G L Amidon,et al. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. , 1996, Advanced drug delivery reviews.
[128] Christos Reppas,et al. Biorelevant Dissolution Testing to Predict the Plasma Profile of Lipophilic Drugs After Oral Administration , 2001, Pharmaceutical Research.
[129] Patrick Poulin,et al. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.
[130] D. Levitt. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol , 2002, BMC clinical pharmacology.
[131] R. Löbenberg,et al. Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.
[132] M. Andersen,et al. A pharmacokinetic model describing pulsatile uptake of orally-administered carbon tetrachloride. , 1997, Toxicology.
[133] B Agoram,et al. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.
[134] Chensheng Lu,et al. Assessing Children’s Dietary Pesticide Exposure: Direct Measurement of Pesticide Residues in 24-Hr Duplicate Food Samples , 2010, Environmental health perspectives.
[135] Martin Kuentz,et al. Drug Absorption Modeling as a Tool to Define the Strategy in Clinical Formulation Development , 2008, The AAPS Journal.
[136] Yatindra Joshi,et al. Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system. , 2004, Journal of pharmaceutical sciences.
[137] Rogelio Tornero-Velez,et al. Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.
[138] M. Durisová,et al. Physiologically motivated time-delay model to account for mechanisms underlying enterohepatic circulation of piroxicam in human beings. , 2009, Basic & clinical pharmacology & toxicology.
[139] Peter Langguth,et al. An Investigation into the Importance of “Very Rapid Dissolution” Criteria for Drug Bioequivalence Demonstration using Gastrointestinal Simulation Technology , 2009, The AAPS Journal.
[140] S. Riegelman,et al. New method for calculating the intrinsic absorption rate of drugs. , 1968, Journal of pharmaceutical sciences.
[141] W. Schmitt,et al. A Physiologic Model for Simulating Gastrointestinal Flow and Drug Absorption in Rats , 2003, Pharmaceutical Research.
[142] M. Odomi,et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[143] Stefan Willmann,et al. Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[144] Lawrence X. Yu,et al. Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development , 2011, The AAPS Journal.
[145] G. Loizou,et al. A human PBPK model for ethanol describing inhibition of gastric motility , 2004, Journal of Molecular Histology.
[146] Stefan Willmann,et al. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. , 2012, Journal of pharmaceutical sciences.